Legend Biotech Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LEGN research report →
About the company
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.
- CEO
- Ying Huang
- IPO
- 2020
- Employees
- 2,900
- HQ
- Somerset, NJ, US
Price Chart
- Market Cap
- $5.53B
- P/E
- -21.99
- P/S
- 4.86
- P/B
- 5.71
- EV/EBITDA
- -29.13
- Div Yield
- 0.00%
- Gross Margin
- 54.99%
- Op Margin
- -11.92%
- Net Margin
- -21.97%
- ROE
- -24.91%
- ROIC
- -9.95%
- Revenue
- $1.03B · 64.04%
- Net Income
- $-296,800,000 · -67.66%
- EPS
- $-1.60 · -64.95%
- Op Income
- $-136,500,000
- FCF YoY
- -6.26%
- 52W High
- $45.30
- 52W Low
- $16.24
- 50D MA
- $29.06
- 200D MA
- $25.49
- Beta
- 0.34
- Avg Volume
- 2.75M
Get TickerSpark's AI analysis on LEGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Casey Patrick John | sell | 6,000 |
| Jun 30, 26 | Huang Ying | other | 3,382 |
| Jun 25, 26 | Huang Ying | sell | 5,566 |
| Mar 25, 26 | Huang Ying | sell | 9,936 |
| Mar 18, 26 | Heyman Tomas J. | other | 0 |
| Mar 18, 26 | Heyman Tomas J. | other | 30,000 |
| Mar 18, 26 | Meng Robin | other | 0 |
| Mar 18, 26 | Salovey Peter | other | 0 |
| Mar 18, 26 | Casey Patrick John | other | 0 |
| Mar 18, 26 | Casey Patrick John | other | 30,000 |
Our LEGN coverage
Recent articles, reports, and earnings notes.
Want a deeper read on LEGN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.